The expression of hepatic transporters, including organic anion transporting polypeptides (OATPs) and multidrug resistance-associated proteins (MRPs), is altered in nonalcoholic steatohepatitis (NASH); however, functional data in humans are lacking. In this study, 99m Tc-mebrofenin (MEB) was used to evaluate OATP1B1/1B3 and MRP2 function in NASH patients. Healthy subjects (n 5 14) and NASH patients (n 5 7) were administered MEB (~2.5 mCi). A population pharmacokinetic model was developed to describe systemic and hepatic MEB disposition. Study subjects were genotyped for SLCO1B1 variants. NASH increased systemic and hepatic exposure (median 6 2 SE, healthy vs. NASH) to MEB (AUC 0-300,blood : 1,780 6 242 vs. 2,440 6 775 lCi*min/L, P 5 0.006; AUC 0-180,liver : 277 6 36.9 vs. 433 6 40.3 kcounts*min/sec, P < 0.0001) due to decreased biliary clearance (0.035 6 0.008 vs. 0.017 6 0.002 L/min, P 5 0.0005) and decreased V central (11.1 6 0.57 vs. 6.32 6 1.02 L, P < 0.0001). MEB hepatic CL uptake was reduced in NASH and also in healthy subjects with SLCO1B1 *15/*15 and *1A/*15 genotypes. The pharmacokinetics of drugs that are OATP1B1/1B3 and MRP2 substrates may be substantially altered in NASH.
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Study Highlights WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
þ Alterations in the expression of some hepatic uptake and efflux transporters in nonalcoholic steatohepatitis (NASH) have been reported previously. However, functional data in patients with NASH are lacking.
WHAT QUESTION DID THIS STUDY ADDRESS?
þ This study was designed to evaluate NASH-mediated changes in OATP1B1/1B3 and MRP2 function using 99m Tcmebrofenin (MEB), a clinical probe for transporter function assessment. A population pharmacokinetic model was developed to quantify changes in systemic and hepatic disposition of MEB in NASH patients compared to healthy subjects.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
þ Patients with NASH exhibited increased systemic and hepatic exposure to MEB, likely due to decreased hepatic uptake and impaired biliary excretion of MEB. HOW THIS MIGHT CHANGE CLINICAL PHARMA-COLOGY OR TRANSLATIONAL SCIENCE þ OATPs and MRP2 are key drug transporters that play an important role in the disposition of many medications, including those commonly used in patients with NASH (e.g., statins, angiotensin receptor antagonists). Therefore, disease-mediated impairment in the function of these transporters, as shown here, may have important clinical implications for the treatment of patients with NASH.
The prevalence of nonalcoholic fatty liver disease (NAFLD) is growing at an alarming rate. Recent literature reports estimate that 20-30% of adults worldwide have NAFLD.
1,2 Some patients with NAFLD will develop nonalcoholic steatohepatitis (NASH), an advanced form of NAFLD characterized by hepatic steatosis, hepatocyte ballooning, and lobular inflammation. 3, 4 NASH is a significant health concern that can progress to advanced fibrosis, cirrhosis, hepatocellular carcinoma, and liver failure, and is predicted to become the leading cause of liver transplantation. 3, [5] [6] [7] [8] Common comorbid conditions in this patient population include obesity, diabetes, hyperlipidemia, hypertriglyceridemia, metabolic syndrome, and hypertension. 2 Many medications used to treat these conditions (e.g., statins, angiotensin II receptor antagonists) are substrates of hepatic transporters. Therefore, potential NASH-mediated changes in hepatic transporter function could alter the pharmacokinetics and efficacy of these drugs in this patient population.
The importance of hepatic transporters in determining the systemic and hepatic exposure to drugs is well established. Changes in transporter function due to drug-drug interactions, genetic variants, or diseases can significantly alter the pharmacokinetics, and in some cases, the pharmacodynamics of drugs. [9] [10] [11] [12] Preclinical models of NASH, and liver tissue from patients with NASH, have shown altered expression of important hepatic uptake and efflux transporters. For example, recent data suggest that organic anion transporting polypeptide (OATP)1B1 is upregulated, while OATP1B3 is downregulated in NASH. 13 Since there is substantial overlap in substrate selectivity between these two uptake transporters, the functional impact of NASH-mediated alterations in hepatic uptake transporters remains to be established in humans. A clinical study evaluating the pharmacokinetics of morphine and its metabolites in patients with NASH demonstrated increased serum morphine glucuronide concentrations, consistent with increased MRP3-mediated basolateral efflux in NASH. 14 However, the expression/function of MRP2, a biliary efflux transporter with similar substrate specificity as MRP3, in patients with NASH is unclear. Previous studies have shown increased MRP2 expression, but this canalicular transporter appears to be mislocalized in liver tissue from patients with NASH. 13, 15 Preclinical models of NASH have shown reduced Mrp2 function and an increased risk of methotrexate-induced hepatic and renal toxicity in NASH. 16 Additionally, both OATP1B1 and OATP1B3, and the efflux transporter MRP2, exhibited decreased levels of the glycosylated protein in liver tissue from patients with NASH compared to control tissues, which may explain the mislocalization of some transporters. [17] [18] [19] The impact of impaired function of efflux transporters can be difficult to study in the clinic because only small changes may occur in systemic concentrations even though there may be extensive changes in hepatic exposure. 20 Hepatic exposure can be assessed using imaging modalities and well-characterized transporter probes (i.e., gamma scintigraphy and 99m Tc-mebrofenin (MEB)). MEB is a nuclear imaging agent used to diagnose or differentiate hepatobiliary abnormalities. MEB is highly extracted by the liver and undergoes negligible metabolism; 98% of the dose is excreted into bile with minimal urinary excretion (1-2% in 24 h). 21 MEB is primarily taken up by OATP1B1 and OATP1B3, and is rapidly excreted by the canalicular transporter MRP2 into bile. [22] [23] [24] Inhibition of OATPs by coadministered drugs can increase MEB systemic exposure. 25 Furthermore, hepatic exposure to MEB and other iminodiacetic acid analogs is prolonged due to genetic impairment of MRP2/Mrp2 in patients with Dubin-Johnson syndrome and in TR -rats. [26] [27] [28] [29] MRP3 also has been shown to transport MEB, but MRP3-mediated basolateral clearance of MEB is substantially lower than MRP2-mediated biliary clearance. 23, 25 The aim of this study was to evaluate the systemic and hepatic disposition of MEB in patients with NASH utilizing population pharmacokinetic (PopPK) modeling to elucidate NASH-mediated changes in hepatic transporter function (i.e., OATPs, MRP2).
RESULTS

Study participants
Twenty-one study participants (14 healthy subjects and 7 patients with biopsy-confirmed NASH) were enrolled in this study, and all completed the study. The two cohorts had similar age and sex distributions, albumin, and creatinine; however the NASH cohort had a higher body weight and body mass index (BMI) ( Table 1) . Based on biopsy results, patients with NASH had an NAFLD activity score (NAS) of 4 or 5, and fibrosis (F1-F3) ( Table 1) .
MEB pharmacokinetics
Blood concentrations and liver count data obtained from gamma scintigraphy after administration of an 2.5 mCi intravenous dose of MEB are shown in Figure 1 . The amount of MEB recovered in urine at 180 min was <1% of the administered dose for both groups, and protein binding of MEB was unchanged in NASH patients compared to healthy subjects ( Table 2) . Pharmacokinetic parameters derived from NCA of the blood and liver data are summarized in Table 2 . The C max and AUC 0-300,blood were increased by 2.1-and 1.4-fold, respectively, in the NASH cohort. The terminal elimination half-life of MEB in blood increased from 190 min to 365 min in the NASH cohort.
Gamma scintigraphy of MEB over 180 min revealed rapid uptake of MEB into the liver. In both cohorts the time-tomaximal activity in the liver (t max,liver ) was 13 min ( Table 2) . Maximal liver activity (X max ) and the area under the MEB liveractivity time curve (AUC 0-180,liver ) were increased by 1.5-fold and 1.6-fold in the NASH cohort, respectively ( Table 2 ). The terminal elimination half-life of MEB in the liver (t 1/2,liver ) increased from 38 min to 50 min in the NASH cohort.
A three-compartment model with blood, liver, and peripheral compartments (Figure 2 ) best described the systemic and hepatic (12) 102 (17) BMI (kg/m 2 ) 24 (2) 33 (5) Albumin (18) 68 (20) ALT (U/L) 29 (10) 110 (60) AST (U/L) 25 (8) 73 ( Figure 3 . Individual pharmacokinetic parameter estimates from the model, stratified by study cohort, are shown in Table 3 . The V central of MEB was decreased (50% lower) in patients with NASH. CL uptake of MEB was reduced 1.6-fold and CL bile was reduced by more than 2-fold in patients with NASH compared to healthy subjects. In addition to disease state (healthy vs. NASH), the effect of genetic variants on MEB disposition also was evaluated. Genetic data were available for 12 healthy subjects and 5 NASH patients. SLCO1B1 (the gene encoding for OATP1B1) haplotypes were assigned functional classification based on clinical guidelines and literature data. 30, 31 In the healthy cohort, one subject had a low function genotype, three subjects had an intermediate function genotype, and the remaining subjects had normal function genotypes; all five NASH patients had normal function genotypes (Supplementary Table S1 ). Hepatic uptake clearance estimates for individual subjects obtained from the pharmacokinetic model were stratified by disease state and OATP1B1 genotype ( Figure 4 ). The reduction in CL uptake in patients with NASH and healthy subjects with the low/intermediate function SLCO1B1 genotype is consistent with decreased function of OATP1B1.
DISCUSSION
This is the first study evaluating NASH-mediated alterations in hepatic transporter function utilizing MEB, an OATP/MRP2 substrate, as a clinical probe. Systemic and hepatic exposure (AUC 0-last ) to MEB after administration of an 2.5 mCi dose was increased in the NASH cohort by 1.4-and 1.6-fold in blood and liver, respectively. Observed changes in MEB disposition Tc-mebrofenin blood concentration vs. time curves and liver scintigraphy vs. time curves in healthy subjects (blue) and patients with NASH (red). Data represent mean 6 SD. Administered dose was calculated by measuring the amount of radioactivity in the syringe containing the prepared dose and subtracting the amount of radioactivity remaining in the syringe, catheter, and tubing after administration. c Data were not available to calculate unbound fraction for 1 healthy subject. Total mass excreted from 0-180 min. Parameters were derived by noncompartmental analysis. CL blood was not reported because the % extrapolated AUC 0-1,blood (median62SE) was 17 6 6.4% in the healthy cohort and 29 6 7.2% in the NASH cohort.
were not due to NASH-mediated alterations in urinary excretion or protein binding. Blood and liver concentration-time profiles of MEB were analyzed using a PopPK modeling approach to elucidate the underlying mechanisms responsible for the differences in systemic and hepatic exposure between the populations. The NASH cohort exhibited increased systemic and hepatic exposure to MEB due to disease-mediated reductions in the central volume of distribution, hepatic uptake clearance, and biliary clearance of MEB.
The C max of MEB after intravenous administration of an 2.5 mCi dose was higher in the NASH cohort due to a reduced volume of distribution of MEB in blood. The volume of distribution is a hypothetical volume that represents the extent of drug distribution in the body rather than a physiological volume. The estimated V central of MEB in healthy subjects (11 L) was similar to previously reported literature values. 23 However, in the NASH cohort the V central of MEB was 50% lower than in healthy subjects, likely due to impaired hepatic uptake of MEB in patients with NASH rather than other underlying physiological changes.
Changes in hepatic uptake clearance can alter the volume of distribution of medications, as discussed previously by Grover and Benet; for example, inhibition of OATP1B1-mediated uptake of atorvastatin by rifampin decreased the atorvastatin volume of distribution. 32 Hepatic uptake can be a major determinant of systemic pharmacokinetics for a drug. The key drug uptake transporters OATP1B1 and OATP1B3 are responsible for the hepatic uptake of numerous medications (including statins, enalapril, and valsartan) and endogenous compounds. These two transporters share 80% amino acid homology and have a high degree of substrate overlap. 33 Interestingly, in liver tissue from patients with NASH, OATP1B1 expression was increased but OATP1B3 expression was decreased; however, OATP1B1 glycosylation was decreased. 13, 17 Additionally, a decrease in hepatic blood flow in patients with NASH 34 could also contribute to a reduced hepatic clearance. In the present study, the hepatic uptake clearance of MEB, a substrate of both OATP1B1 and OATP1B3, was reduced in the NASH cohort. Medications used in patients with NASH to treat common comorbid conditions such as hyperlipidemia (rosuvastatin and pravastatin) and hypertension (enalapril, olmesartan, and valsartan) are also substrates of both OATP1B1 and OATP1B3. The hepatic uptake of these commonly used medications also may be decreased in patients with NASH, as shown with MEB.
Genetic polymorphisms can alter the function of OATP1B1 in addition to NASH-mediated changes in OATP1B1 function. The *15 haplotype is associated with reduced OATP1B1 function, and homozygous patients are characterized as low function; patients who are heterozygous for the *15 allele are classified as exhibiting intermediate OATP1B1 function. 30, 31 Healthy subjects with either the low or intermediate function OATP1B1 genotypes exhibited a lower hepatic uptake clearance of MEB compared to healthy subjects with the normal function genotype (Figure 4) . Surprisingly, NASH patients with a normal OATP function genotype exhibited a lower hepatic uptake clearance of MEB than the healthy subjects with impaired function genotypes ( Figure 4) . Although genetic polymorphisms in OATP1B1 can reduce the uptake of MEB, the magnitude of this decrease Tcmebrofenin disposition. The final structural model that best described the data included a central, peripheral, and a liver compartment. appears to be less than the reduction in hepatic uptake of MEB due to NASH-related changes. The synergistic effect of genetic polymorphisms and NASH on transporter function was evaluated in Oatp1b2 knockout mice with diet-induced NASH; pravastatin plasma exposure was highest in Oatp1b2 knockout mice with diet-induced NASH compared to control mice or mice with either diet-induced NASH or Oatp1b2 knockout alone. 13 Additional studies should be conducted to evaluate the interaction and functional impact of genetic polymorphisms and NASH-mediated alterations in hepatic transporter function.
Although changes in hepatic uptake clearance can cause important differences in systemic pharmacokinetics, alterations in hepatic efflux transporters typically have the most significant impact on hepatic exposure. 35 Patients with NASH exhibited an 1.6-fold increase in hepatic exposure to MEB that was due primarily to decreased biliary excretion. Median (62 SE) CL bile was 0.017 6 0.002 L/min in the NASH cohort compared to 0.035 6 0.008 L/min in the healthy cohort. Biliary excretion of MEB is mediated by MRP2, an adenosine triphosphate (ATP)-dependent canalicular transporter with broad specificity for both endogenous substrates as well as drugs and metabolites (glutathione and glucuronide conjugates). Reduced function of this canalicular transporter may alter the pharmacokinetics of medications that are MRP2 substrates, including methotrexate, statins, enalapril, olmesartan, valsartan, fexofenadine, and glucuronide metabolites of mycophenolic acid. 36, 37 In liver tissue from patients with NASH, although MRP2 expression was increased, it appeared to be mislocalized from the canalicular membrane, likely due to reduced glycosylation 15, 17 ; unglycosylated MRP2 may not be functional. 18, 19 These findings are consistent with reduced MRP2 function observed in the present study. Impaired MRP2 function (due to diseases, genetic variants, or drug interactions) can have a substantial impact on the hepatic exposure to a compound, as shown for the first time in this clinical study. This may have significant clinical implications in the treatment of NASH patients with drugs that are MRP2 substrates and that have a site of action (efficacy or toxicity) in the liver.
MRP3, a hepatic basolateral efflux transporter that exhibits extensive substrate overlap with MRP2, can serve as a compensatory pathway in conditions where MRP2 is downregulated. 38, 39 Patients with NASH have increased MRP3 expression 15 and function as demonstrated by an increase in systemic concentrations of glucuronide metabolites of morphine.
14 However, the two cohorts were similar in median basolateral efflux clearance of MEB (CL efflux ). Although in vitro membrane vesicle studies have shown that MEB is a substrate for MRP3, the overall contribution of MRP3-mediated basolateral efflux clearance in the disposition of MEB is minimal. The ratio of biliary to basolateral efflux clearance for healthy subjects was 4.5, consistent with our previous study, and indicates that MEB is not a sensitive clinical probe for assessing MRP3 function. 23, 25 To define a homogenous population and reduce the impact of confounding variables, subjects were excluded if they had evidence of cirrhosis, portal hypertension, decompensated liver disease, a history of immune-related disease, bariatric surgery, a history of drugs associated with fatty liver disease or steatohepatitis, or if they were taking any Type 2 diabetes medications other than metformin, or any medication that might interact with OATPs/MRP2. Patients with a histological confirmation of NASH with an NAS score of >3 were enrolled because changes in transporter expression are expected after the onset of inflammation. 15 Additionally, intensive sampling was conducted to help reduce the number of patients required to develop the PopPK model.
In conclusion, patients with biopsy-confirmed NASH displayed increased systemic and hepatic exposure to MEB, and biliary clearance was decreased by more than 2-fold, compared to age-and sex-matched healthy subjects. Specifically, these changes are consistent with NASH-associated decreases in hepatic uptake (mediated by OATP1B1 and OATP1B3) and biliary clearance (mediated by MRP2). Given the increasing prevalence of NASH, the impact of hepatic transporter dysregulation on the systemic and hepatic exposure to drugs and their metabolites should be considered carefully when treating patients with steatohepatitis. Medications with characteristics similar to MEB (high protein binding, substrates of OATP1B1/1B3 and/or MRP2, biliary excretion with negligible renal elimination) that are likely to be prescribed to patients with NASH include statins, repaglinide, olmesartan, and fexofenadine. Clinical data regarding altered pharmacokinetics of these drugs in patients with NASH is currently lacking, and additional studies should be conducted. Importantly, the impact of decreased hepatic uptake and/or impaired biliary excretion mediated by OATP1B1 and MRP2, respectively, in patients with biopsy-confirmed NASH on compounds in drug development should be considered carefully. NASH-mediated changes in transporter function could affect the systemic concentrations, pharmacodynamic effects, and/or toxicity of medications that have pharmacokinetic properties similar to MEB, especially when the liver is the site of action. Further understanding of how NASH affects hepatic and extrahepatic clearance mechanisms will improve our ability to predict drug disposition, efficacy, and safety of new and existing medications in this patient population.
METHODS
Study participants
This single-center, observational, cohort-comparison study enrolled healthy subjects and patients with biopsy-confirmed NASH between 18 and 65 years of age. Subjects with self-reported drinking >20 g/day of alcohol, or a history of gastrointestinal surgery, autoimmune disease, or other gastrointestinal/liver abnormalities were excluded. At screening, healthy subjects had clinical chemistry and coagulation panel measurements within the normal range as determined by the McLendon Clinical Laboratories at UNC Medical Center, Chapel Hill, North Carolina. All enrolled subjects exhibited normal values for serum creatinine, total bilirubin, and negative results for HIV antigen, hepatitis B surface antigen, and hepatitis C antibody. Additionally, the enrolled healthy subjects had a homeostatic model assessment for insulin resistance (HOMA-IR) score <2.5, BMI 30 kg/m 2 , and were not taking any medications or herbal products other than oral contraceptives or a daily multivitamin.
Patients with biopsy-confirmed, noncirrhotic NASH were recruited from the UNC-CH Hepatology Clinic and were enrolled if they met the following inclusion criteria: nonalcoholic fatty liver disease activity score (NAS) >3, BMI 45 kg/m 2 , no treatment for Type 2 diabetes other than metformin, no milk thistle products or high-dose antioxidant treatment during the prior 30 days (e.g., vitamin E), and absence of prior treatment with NASH-associated drugs (i.e., tamoxifen, amiodarone, methotrexate, prednisone, tetracyclines, or valproic acid). If NASH patients were taking medications that might interact with OATPs/ MRP2, these medications were withheld for a washout period of 5 halflives, if determined clinically appropriate by the study physician. Otherwise, the patient was excluded from the study.
Written informed consent was obtained from all subjects. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the UNC-CH Biomedical Institutional Review Board, and was registered at ClinicalTrials.gov (NCT02235233).
Study design
Subjects and patients who met all inclusion/exclusion criteria were admitted to the Clinical and Translational Research Center at UNC-CH Hospitals after fasting overnight. Vital signs were assessed, and an intravenous catheter was placed in one arm delivering a normal saline drip, which was used for drawing blood samples during the study. Prior to MEB administration, a transmission acquisition was performed using a cobalt-57 flood source (Isotope Products Laboratories, Burbank, CA) positioned posteriorly, and gamma rays were detected in the cobalt window (122 KeV 6 15%) for 5-10 min on the anterior detector in the absence and presence of the study participant to obtain a subject-specific attenuation correction factor. An 2.5 mCi intravenous bolus dose of MEB was administered via an indwelling catheter placed in a contralateral forearm or hand vein, which was removed after drug administration. Blood samples (3 mL) were collected at baseline (0), 2.5, 5, 7.5, 10, 15, 20, 40, 60, 80, 100, 120, 140, 160, 180, 210, 240, 270 , and 300 min after administration; urine samples were collected at baseline (0) and at 180 min after administration. Anterior and posterior scintigraphic images of the abdomen were acquired dynamically in the 99m Tc window (140 KeV 6 15%) at 1-min intervals using a dual headed gamma camera up to 180 min after MEB administration. Liver activity-time curves were generated as described previously using Syngo MI applications v. 6.5.9.19 (Siemens, New York, NY). 25 Prior to discharge, vital signs were assessed and study participants were administered a safety questionnaire.
Blood and urine samples were analyzed for MEB radioactivity with a sodium iodide well counter and corrected for decay ( 99m Tc t 1/2 5 6.01 h). A blood sample (3 mL) collected at 20 min postdose was centrifuged to obtain serum; 0.6 mL of serum was filtered through a CentrifreeT ultrafiltration membrane system (Millipore Ireland, Tullagreen, Cork, Ireland) according to the manufacturer's instructions to obtain 10% of the initial volume as ultrafiltrate to quantify the unbound fraction of MEB in serum as described previously. 23 Genomic DNA was extracted using the 
Pharmacokinetic data analysis
Blood concentration-time and the liver counts/sec-time profiles were used to conduct a noncompartmental analysis (NCA) using Phoenix WinNonlin v. 7 (Certara USA, Princeton, NJ). The area under the blood concentration-time curve and the liver activity-time curve from time zero to the last timepoint (AUC 0-300,blood and AUC 0-180,liver , respectively) were calculated using a linear-up log-down trapezoidal algorithm. The terminal half-life was calculated as 0.693/k z , where k z was estimated from the terminal elimination phase. The percentage of the dose excreted in urine was calculated by dividing the total mass of MEB in urine after 180 min (the product of urine concentration and total volume collected) by the administered dose.
In addition to the NCA, a PopPK model was developed using ordinary differential equations to describe the disposition of MEB in the blood and liver using the Quasi-random Parametric Expectation Maximization (QRPEM) estimation method in Phoenix WinNonlin v. 7. Various structural models were evaluated, including models without a peripheral compartment, and with two liver subcompartments. The final model was selected based on the objective function values, overall model fit, and diagnostic plots. Urinary excretion of MEB was not included in the model because it was not a major route of elimination (<1% of the dose was recovered in urine after 180 min). Liver concentrations were obtained by converting liver counts to amount using an instrumentspecific conversion factor of 193 cpm/lCi and dividing by the estimated liver volume calculated for each individual subject using a previously published formula based on body surface area. 40 The volume of the peripheral compartment was estimated to be 1.5 L in the initial iterations of the model, and was fixed at this value for subsequent runs. A multiplicative error model was used for blood and liver concentrations, and an exponential random effects model was used for interindividual variability on the model parameters.
The effects of potential covariates (body weight and NASH disease status) on V central , CL uptake , CL bile , and CL efflux were evaluated using a forward-inclusion, backward-elimination, stepwise algorithm. A visual predictive check was performed with 100 replicates using the parameter and interindividual variability estimates from the final model to evaluate the performance of the model ( Figure S1 ). The final version of the PopPK model was used to compute parameter estimates for each NASH patient and each healthy participant to evaluate the impact of NASH.
Statistical analysis strategy
Individual-specific estimates of MEB blood and liver pharmacokinetic parameters from the NCA and from the PopPK model were used to characterize and compare the two cohorts. Median differences between the two cohorts were estimated using the Hodges-Lehmann estimator (HLE) of location shift for two-sample data. The HLE was tabulated along with the corresponding 95% confidence interval for the median difference. The Mann-Whitney-Wilcoxon test was used to detect differences in pharmacokinetic parameters between the healthy and NASH cohorts. All statistical computations were conducted using GraphPad Prism v. 7.00 for Windows (GraphPad Software, La Jolla, CA).
Additional Supporting Information may be found in the online version of this article.
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